TCB-2

TCB-2 is a psychedelic drug that was first synthesized by Alexander Shulgin. It is a potent and selective partial agonist for the serotonin 5-HT2A receptor, and is thought to be a research chemical that has been sold online as a designer drug.

Chemistry

TCB-2 is a member of the 25-NB family. It is structurally related to 2C-B and DOB, with the 4-bromo group of 2C-B replaced by a 4-chloro group, and the 2,5-dimethoxy groups of DOB replaced by 2,5-dichloro groups.

Pharmacology

TCB-2 is a partial agonist at the 5-HT2A receptor. It has a high affinity for this receptor, with a Ki of 0.25 nM. This makes it around 6 times more potent than DOB, and slightly less potent than LSD.

Effects

The effects of TCB-2 are not well documented, as it is a relatively new substance. However, it is thought to produce effects similar to other psychedelic drugs, such as visual hallucinations, altered perception, and euphoria.

Legal Status

In the United States, TCB-2 is not specifically listed as a controlled substance, but it may be considered an analog of 2C-B or DOB, which are Schedule I drugs under the Controlled Substances Act.

See Also

• 25-NB
• 2C-B
• DOB
• LSD
• Psychedelic drug
• Designer drug

References

TCB-2 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia